Edition:
India

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

15.15USD
17 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$15.15
Open
$15.10
Day's High
$15.20
Day's Low
$14.85
Volume
42,961
Avg. Vol
58,066
52-wk High
$20.55
52-wk Low
$7.30

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

BRIEF-Stemline Therapeutics Reports Q1 Loss Per Share $0.69

* STEMLINE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

10 May 2018

BRIEF-Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares

* STEMLINE THERAPEUTICS INC - ‍ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK​ Source text (http://bit.ly/2HHHaYN) Further company coverage: (Reuters.Brief@thomsonreuters.com)

17 Mar 2018

BRIEF-Stemline Therapeutics Q4 Loss Per Share $0.93

* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

16 Mar 2018

Competitors

Earnings vs. Estimates